SVB Leerink analyst Jonathan Chang maintains Macrogenics (NASDAQ:MGNX) with a Outperform and raises the price target from $37 to $40.
Uncategorized
SVB Leerink Maintains Outperform on Macrogenics, Raises Price Target to $40
SVB Leerink analyst Jonathan Chang maintains Macrogenics (NASDAQ:MGNX) with a Outperform and raises the price target from $37 to $40.
Related Posts
IonQ Reports Plans To Use Barium Ions As Qubits In Its Systems
Barium qubits are highly stable and offer many ways to increase computing fidelity and speed
Technology allows IonQ to use standard photonics devices to build more reliable quantum computers
Barium enables IonQ to more
Microbot Medical Reports Initiation Of Search For US Clinical Sites For LIBERTY Robotic System
Microbot Medical Inc. (NASDAQ:MBOT) announced that it has and will continue to implement key initiatives that will prepare the LIBERTY® Robotic System for commercialization. In conjunction with recently announced
Canadian Pacific Railway’s Return on Invested Capital Overview
According to Benzinga Pro, during Q2, Canadian Pacific Railway (NYSE:CP) earned $480.00 million, a 11.37% increase from the preceding quarter. Canadian Pacific Railway also posted a total of $1.73 billion in sales, a 18.95% increase since Q1.